Sader Helio S, Smart Jennifer I, Mendes Rodrigo E, Castanheira Mariana
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0140224. doi: 10.1128/aac.01402-24. Epub 2025 Jan 13.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates. A total of 19,764 . isolates were collected from patients with various infection types at 37 US medical centers from 2016 to 2022. Susceptibility testing was performed by broth microdilution according to Clinical and Laboratory Standard Institutes (CLSI) standards. Isolates were categorized as MDR if they were nonsusceptible by CLSI criteria to ≥3 antimicrobials. Ceftobiprole was highly active against MRSA ( = 8,184; MIC, 1/2 mg/L; 99.3% susceptible [S]) and MDR ( = 2,789; MIC, 1/2 mg/L; 98.1%S) isolates and retained activity against 87.3% of ceftaroline-nonsusceptible isolates ( = 433; MIC, 2/4 mg/L). Ceftobiprole demonstrated greater susceptibility rates than ceftaroline against all resistant subsets. Ceftobiprole was highly active against isolates nonsusceptible to clindamycin (98.0%S), daptomycin (100.0%S), doxycycline (98.2%S), erythromycin (99.5%S), gentamicin (98.1%S), levofloxacin (99.1%S), tetracycline (99.1%S), tigecycline (100.0%S), and trimethoprim-sulfamethoxazole (99.4%S) and isolates with decreased susceptibility to vancomycin (98.3%S).
头孢比普最近获得美国食品药品监督管理局（FDA）批准，用于治疗患有菌血症的成年患者，包括右侧心内膜炎、急性细菌性皮肤及皮肤结构感染，以及成人和儿童社区获得性细菌性肺炎。头孢比普是新一代头孢菌素，在许多国家被批准用于治疗成人社区获得性肺炎和医院获得性肺炎，但不包括呼吸机相关性肺炎。我们评估了头孢比普和对照药物对耐甲氧西林金黄色葡萄球菌（MRSA）和多重耐药（MDR）临床分离株的活性。2016年至2022年期间，在美国37个医疗中心从患有各种感染类型的患者中总共收集了19764株分离株。根据临床和实验室标准协会（CLSI）标准，通过肉汤微量稀释法进行药敏试验。如果分离株根据CLSI标准对≥3种抗菌药物不敏感，则将其分类为MDR。头孢比普对MRSA（n = 8184；MIC，1/2 mg/L；99.3%敏感[S]）和MDR（n = 2789；MIC，1/2 mg/L；98.1%S）分离株具有高活性，并且对87.3%的对头孢洛林不敏感的分离株（n = 433；MIC，2/4 mg/L）保持活性。在所有耐药亚组中，头孢比普显示出比头孢洛林更高的敏感率。头孢比普对克林霉素不敏感的分离株（98.0%S）、达托霉素（100.0%S）、多西环素（98.2%S）、红霉素（99.5%S）、庆大霉素（98.1%S）、左氧氟沙星（99.1%S）、四环素（99.1%S）、替加环素（100.0%S）和甲氧苄啶 - 磺胺甲恶唑（99.4%S）以及对万古霉素敏感性降低的分离株（98.3%S）具有高活性。
